Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Lee, CH
- Shah, AY
- Hsieh, JJ
- Rao, A
- Pinto, A
- Bilen, MA
- Cohn, AL
- Di Simone, C
- Shaffer, DR
- Ribe, SG
- Wu, J
- Schmidt, EV
- Perini, RF
- Kubiak, P
- Smith, AD
- Motzer, RJ
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Lee,CH,Shah,AY,Hsieh,JJ,Rao,A,Pinto,A,Bilen,MA,Cohn,AL et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2020. ELECTR NETWORK-MAY 29-31. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2020.
Portal de investigación